The increase in price target by Goldman Sachs, a major financial institution, suggests a positive adjustment in the valuation of Revance Therapeutics. While the Neutral rating indicates a cautious stance, the raised target implies an expectation of some upside potential. This could lead to a short-term positive sentiment among investors, potentially driving the stock price up.